Helicobacter Pylori Eradication Clinical Trial
Official title:
Clinical Study on Bifidobacterium Quadruple Live Bacteria Tablets (Si Lian Kang) Reducing the Incidence Rate of Adverse Reactions in Helicobacter Pylori Quadruple Eradication Therapy and on the Effects of Gastrointestinal Flora
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple eradication therapy and its influence on gastrointestinal flora.
Bismuth agent quadruple therapy (including bismuth agent and proton pump inhibitor combined with two antibiotics) is the first-line strategy to eradicate Helicobacter pylori in China. However, it may cause a series of adverse reactions, such as nausea, diarrhea, abdominal pain, constipation, and abnormal taste, etc., which leads to a decrease in patient compliance, thereby affecting the treatment effect. Many studies have found that adding probiotics to traditional Helicobacter pylori eradication therapies increase eradication rates and reduce the side effects of the treatment. Bifidobacterium tetrad live bacteria tablet is a compound microecological preparation composed of bifidobacterium infantis, lactobacillus acidophilus, enterococcus faecalis and bacillus cereus. This study aims to observe the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions in Helicobacter pylori quadruple eradication therapy and on the effects of gastrointestinal flora. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02873065 -
Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori
|
Phase 4 | |
| Recruiting |
NCT06349486 -
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
|
N/A | |
| Completed |
NCT03924375 -
Serum Pepsinogen After H. Pylori Eradication
|
||
| Completed |
NCT04850209 -
The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori
|
N/A | |
| Not yet recruiting |
NCT04558502 -
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
|
Phase 4 | |
| Completed |
NCT06101420 -
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
|
Phase 3 | |
| Recruiting |
NCT06088316 -
Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT
|
Phase 4 | |
| Recruiting |
NCT05850117 -
Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p
|
N/A | |
| Recruiting |
NCT05191888 -
14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
|
Phase 4 | |
| Recruiting |
NCT05870397 -
Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial
|
N/A |